Patent intelligence · US
US 12221422
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
Patent details — US 12221422
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 11, 2025
- Expiration
- Feb 6, 2045
- Applicant
- CENTESSA PHARMACEUTICALS (UK) LIMITED
- Claims
- 10
- CPC classes
- A61K, A61K31/513, A61K9/0053, A61P
Quick answer
US 12221422 (Compounds and their use for the treatment of alpha1-antitrypsin deficiency) is held by CENTESSA PHARMACEUTICALS (UK) LIMITED. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CENTESSA PHARMACEUTICALS (UK) LIMITED
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/513, A61K9/0053, A61P, A61P1/16, A61P11/06
More from CENTESSA PHARMACEUTICALS (UK) LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12421310
CD47 binding agents
granted -
US 12415861
Anti C-MET antibodies
granted -
US 12365672
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12291507
Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
granted -
US 12286402
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
granted -
US 12227580
Antigen binding molecules that bind LIGHT
granted
Frequently asked questions
What is US patent 12221422?
US 12221422 (Compounds and their use for the treatment of alpha1-antitrypsin deficiency) is held by CENTESSA PHARMACEUTICALS (UK) LIMITED. Status: granted. Granted Feb 11, 2025. Expires Feb 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12221422?
CENTESSA PHARMACEUTICALS (UK) LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12221422 expire?
Our index shows an expiration date of Feb 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.